Diphenoxylate Hydrochloride And Atropine Sulfate

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Therapeutic category
Active ingredient (INN)	Diphenoxylate Hydrochloride And Atropine Sulfate

Controlled substance	No

Marketing-authorisation holders	HIKMA PHARMACEUTICALS USA INC., SpecGx LLC

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 2 MA holders

Product	Strength	Form	Market	MA holder	Status
Diphenoxylate Hydrochloride and Atropine Sulfate	.025; 2.5mg/5mL; mg/5mL	solution	🇺🇸 US	HIKMA PHARMACEUTICALS USA INC.	Active
Diphenoxylate Hydrochloride and Atropine Sulfate	.025; 2.5mg/1; mg/1	tablet	🇺🇸 US	SpecGx LLC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.